|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Okuda K: Early recognition of
hepatocellular carcinoma. Hepatology. 6:729–738. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuo KL, Stenehjem D, Albright F, Ray S and
Brixner D: Treatment patterns and outcomes in patients with
hepatocellular carcinoma stratified by stage-guided treatment
categories. J Natl Compr Canc Netw. 13:987–994. 2015.PubMed/NCBI
|
|
4
|
Song S, Nam SW, Bae SH, Kim JD, Jang JW,
Song MJ, Lee SW, Kim HY, Lee YJ, Chun HJ, et al: Outcome of
transarterial chemoembolization-based multi-modal treatment in
patients with unresectable hepatocellular carcinoma. World J
Gastroenterol. 21:2395–2404. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Song Y, Wang F, Huang Q, Cao Y, Zhao Y and
Yang C: MicroRNAs contribute to hepatocellular carcinoma. Mini Rev
Med Chem. 15:459–466. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ranganathan K and Sivasankar V: MicroRNAs
- Biology and clinical applications. J Oral Maxillofac Pathol.
18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Yao J, Zhang X, Guo B, Le X,
Cubberly M, Li Z, Nan K, Song T and Huang C: miRNA-302b suppresses
human hepato-cellular carcinoma by targeting AKT2. Mol Cancer Res.
12:190–202. 2014. View Article : Google Scholar
|
|
11
|
Liu J, Yan J, Zhou C, Ma Q, Jin Q and Yang
Z: miR-1285-3p acts as a potential tumor suppressor miRNA via
downregulating JUN expression in hepatocellular carcinoma. Tumour
Biol. 36:219–225. 2015. View Article : Google Scholar
|
|
12
|
Kan H, Guo W, Huang Y and Liu D:
MicroRNA-520g induces epithelial-mesenchymal transition and
promotes metastasis of hepatocellular carcinoma by targeting SMAD7.
FEBS Lett. 589:102–109. 2015. View Article : Google Scholar
|
|
13
|
Li T, Yin J, Yuan L, Wang S, Yang L, Du X
and Lu J: Downregulation of microRNA-139 is associated with
hepatocellular carcinoma risk and short-term survival. Oncol Rep.
31:1699–1706. 2014.PubMed/NCBI
|
|
14
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
Simultaneously expressed miR-424 and miR-381 synergistically
suppress the proliferation and survival of renal cancer cells -
Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao
Paulo). 68:825–833. 2013. View Article : Google Scholar
|
|
15
|
Rothschild SI, Tschan MP, Jaggi R, Fey MF,
Gugger M and Gautschi O: MicroRNA-381 represses ID1 and is
deregulated in lung adenocarcinoma. J Thorac Oncol. 7:1069–1077.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nadolny C and Dong X: Liver receptor
homolog-1 (LRH-1): A potential therapeutic target for cancer.
Cancer Biol Ther. 16:997–1004. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paré JF, Malenfant D, Courtemanche C,
Jacob-Wagner M, Roy S, Allard D and Bélanger L: The fetoprotein
transcription factor (FTF) gene is essential to embryogenesis and
cholesterol homeostasis and is regulated by a DR4 element. J Biol
Chem. 279:21206–21216. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duggavathi R, Volle DH, Mataki C, Antal
MC, Messaddeq N, Auwerx J, Murphy BD and Schoonjans K: Liver
receptor homolog 1 is essential for ovulation. Genes Dev.
22:1871–1876. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Large MJ, Duggavathi R, DeMayo
FJ, Lydon JP, Schoonjans K, Kovanci E and Murphy BD: Liver receptor
homolog-1 is essential for pregnancy. Nat Med. 19:1061–1066. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu TT, Makishima M, Repa JJ, Schoonjans K,
Kerr TA, Auwerx J and Mangelsdorf DJ: Molecular basis for feedback
regulation of bile acid synthesis by nuclear receptors. Mol Cell.
6:507–515. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mataki C, Magnier BC, Houten SM, Annicotte
JS, Argmann C, Thomas C, Overmars H, Kulik W, Metzger D, Auwerx J,
et al: Compromised intestinal lipid absorption in mice with a
liver-specific deficiency of liver receptor homolog 1. Mol Cell
Biol. 27:8330–8339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Oosterveer MH, Mataki C, Yamamoto H,
Harach T, Moullan N, van Dijk TH, Ayuso E, Bosch F, Postic C, Groen
AK, et al: LRH-1-dependent glucose sensing determines intermediary
metabolism in liver. J Clin Invest. 122:2817–2826. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schoonjans K, Dubuquoy L, Mebis J, Fayard
E, Wendling O, Haby C, Geboes K and Auwerx J: Liver receptor
homolog 1 contributes to intestinal tumor formation through effects
on cell cycle and inflammation. Proc Natl Acad Sci USA.
102:2058–2062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Benod C, Vinogradova MV, Jouravel N, Kim
GE, Fletterick RJ and Sablin EP: Nuclear receptor liver receptor
homologue 1 (LRH-1) regulates pancreatic cancer cell growth and
proliferation. Proc Natl Acad Sci USA. 108:16927–16931. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bayrer JR, Mukkamala S, Sablin EP, Webb P
and Fletterick RJ: Silencing LRH-1 in colon cancer cell lines
impairs proliferation and alters gene expression programs. Proc
Natl Acad Sci USA. 112:2467–2472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang SL, Zheng DZ, Lan FH, Deng XJ, Zeng
J, Li CJ, Wang R and Zhu ZY: Increased expression of hLRH-1 in
human gastric cancer and its implication in tumorigenesis. Mol Cell
Biochem. 308:93–100. 2008. View Article : Google Scholar
|
|
27
|
Chand AL, Wijayakumara DD, Knower KC,
Herridge KA, Howard TL, Lazarus KA and Clyne CD: The orphan nuclear
receptor LRH-1 and ERα activate GREB1 expression to induce breast
cancer cell proliferation. PLoS One. 7:e315932012. View Article : Google Scholar
|
|
28
|
Chand AL, Pathirage N, Lazarus K, Chu S,
Drummond AE, Fuller PJ and Clyne CD: Liver receptor homologue-1
expression in ovarian epithelial and granulosa cell tumours.
Steroids. 78:700–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Botrugno OA, Fayard E, Annicotte JS, Haby
C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J,
et al: Synergy between LRH-1 and beta-catenin induces G1
cyclin-mediated cell proliferation. Mol Cell. 15:499–509. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pez F, Lopez A, Kim M, Wands JR, Caron de
Fromentel C and Merle P: Wnt signaling and hepatocarcinogenesis:
Molecular targets for the development of innovative anticancer
drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Corzo CA, Mari Y, Chang MR, Khan T,
Kuruvilla D, Nuhant P, Kumar N, West GM, Duckett DR, Roush WR, et
al: Antiproliferation activity of a small molecule repressor of
liver receptor homolog 1. Mol Pharmacol. 87:296–304. 2015.
View Article : Google Scholar :
|
|
32
|
Wang S, Lan F, Huang L, Dong L, Zhu Z, Li
Z, Xie Y and Fu J: Suppression of hLRH-1 mediated by a DNA
vector-based RNA interference results in cell cycle arrest and
induction of apoptosis in hepatocellular carcinoma cell BEL-7402.
Biochem Biophys Res Commun. 333:917–924. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gu P, Goodwin B, Chung AC, Xu X, Wheeler
DA, Price RR, Galardi C, Peng L, Latour AM, Koller BH, et al:
Orphan nuclear receptor LRH-1 is required to maintain Oct4
expression at the epiblast stage of embryonic development. Mol Cell
Biol. 25:3492–3505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kelly VR and Hammer GD: LRH-1 and Nanog
regulate Dax1 transcription in mouse embryonic stem cells. Mol Cell
Endocrinol. 332:116–124. 2011. View Article : Google Scholar :
|
|
35
|
Gerrits H, Paradé MC, Koonen-Reemst AM,
Bakker NE, Timmer-Hellings L, Sollewijn Gelpke MD and Gossen JA:
Reversible infertility in a liver receptor homologue-1
(LRH-1)-knockdown mouse model. Reprod Fertil Dev. 26:293–306. 2014.
View Article : Google Scholar
|
|
36
|
Zhou J, Suzuki T, Kovacic A, Saito R, Miki
Y, Ishida T, Moriya T, Simpson ER, Sasano H and Clyne CD:
Interactions between prostaglandin E(2), liver receptor
homologue-1, and aromatase in breast cancer. Cancer Res.
65:657–663. 2005.PubMed/NCBI
|
|
37
|
Bouchard MF, Taniguchi H and Viger RS:
Protein kinase A-dependent synergism between GATA factors and the
nuclear receptor, liver receptor homolog-1, regulates human
aromatase (CYP19) PII promoter activity in breast cancer cells.
Endocrinology. 146:4905–4916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lanzino M, Maris P, Sirianni R, Barone I,
Casaburi I, Chimento A, Giordano C, Morelli C, Sisci D, Rizza P, et
al: DAX-1, as an androgen-target gene, inhibits aromatase
expression: A novel mechanism blocking estrogen-dependent breast
cancer cell proliferation. Cell Death Dis. 4:e7242013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Annicotte JS, Chavey C, Servant N,
Teyssier J, Bardin A, Licznar A, Badia E, Pujol P, Vignon F,
Maudelonde T, et al: The nuclear receptor liver receptor homolog-1
is an estrogen receptor target gene. Oncogene. 24:8167–8175.
2005.PubMed/NCBI
|
|
40
|
Thiruchelvam PT, Lai CF, Hua H, Thomas RS,
Hurtado A, Hudson W, Bayly AR, Kyle FJ, Periyasamy M, Photiou A, et
al: The liver receptor homolog-1 regulates estrogen receptor
expression in breast cancer cells. Breast Cancer Res Treat.
127:385–396. 2011. View Article : Google Scholar
|
|
41
|
Lai CF, Flach KD, Alexi X, Fox SP,
Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua
H, et al: Co-regulated gene expression by oestrogen receptor α and
liver receptor homolog-1 is a feature of the oestrogen response in
breast cancer cells. Nucleic Acids Res. 41:10228–10240. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chand AL, Herridge KA, Thompson EW and
Clyne CD: The orphan nuclear receptor LRH-1 promotes breast cancer
motility and invasion. Endocr Relat Cancer. 17:965–975. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bianco S, Jangal M, Garneau D and Gévry N:
LRH-1 controls proliferation in breast tumor cells by regulating
CDKN1A gene expression. Oncogene. 34:4509–4518. 2015. View Article : Google Scholar
|
|
44
|
Cai YN, Zhou Q, Kong YY, Li M, Viollet B,
Xie YH and Wang Y: LRH-1/hB1F and HNF1 synergistically up-regulate
hepatitis B virus gene transcription and DNA replication. Cell Res.
13:451–458. 2003. View Article : Google Scholar
|
|
45
|
Rey J, Hu H, Kyle F, Lai CF, Buluwela L,
Coombes RC, Ortlund EA, Ali S, Snyder JP and Barrett AG: Discovery
of a new class of liver receptor homolog-1 (LRH-1) antagonists:
Virtual screening, synthesis and biological evaluation.
ChemMedChem. 7:1909–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Benod C, Carlsson J, Uthayaruban R, Hwang
P, Irwin JJ, Doak AK, Shoichet BK, Sablin EP and Fletterick RJ:
Structure-based discovery of antagonists of nuclear receptor LRH-1.
J Biol Chem. 288:19830–19844. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Anwar SL and Lehmann U: MicroRNAs:
Emerging novel clinical biomarkers for hepatocellular carcinomas. J
Clin Med. 4:1631–1650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang J, Liu X, Yuan X and Wang Z: miR-99b
promotes metastasis of hepatocellular carcinoma through inhibition
of claudin 11 expression and may serve as a prognostic marker.
Oncol Rep. 34:1415–1423. 2015.PubMed/NCBI
|
|
49
|
Chen B, Duan L, Yin G, Tan J and Jiang X:
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer
cells to 5-FU by up-regulation of Cdc2 activities in 786-O. J
Chemother. 25:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y,
Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381
and miR-495 are inversely associated with the expression of the
MDR1 gene and development of multi-drug resistance. PLoS One.
8:e820622013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agró E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G
and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar
|
|
52
|
Tang H, Liu X, Wang Z, She X, Zeng X, Deng
M, Liao Q, Guo X, Wang R, Li X, et al: Interaction of hsa-miR-381
and glioma suppressor LRRC4 is involved in glioma growth. Brain
Res. 1390:21–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tang H, Wang Z, Liu Q, Liu X, Wu M and Li
G: Disturbing miR-182 and -381 inhibits BRD7 transcription and
glioma growth by directly targeting LRRC4. PLoS One. 9:e841462014.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang Z, Yang J, Xu G, Wang W, Liu C, Yang
H, Yu Z, Lei Q, Xiao L, Xiong J, et al: Targeting miR-381-NEFL axis
sensitizes glioblastoma cells to temozolomide by regulating
stemness factors and multidrug resistance factors. Oncotarget.
6:3147–3164. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Papp G, Krausz T, Stricker TP, Szendrői M
and Sápi Z: SMARCB1 expression in epithelioid sarcoma is regulated
by miR-206, miR-381, and miR-671-5p on both mRNA and protein
levels. Genes Chromosomes Cancer. 53:168–176. 2014. View Article : Google Scholar
|
|
56
|
Li Z, Wu S, Lv S, Wang H, Wang Y and Guo
Q: Suppression of liver receptor homolog-1 by microRNA-451
represses the proliferation of osteosarcoma cells. Biochem Biophys
Res Commun. 461:450–455. 2015. View Article : Google Scholar : PubMed/NCBI
|
